FGF23 and left ventricular hypertrophy: Calcimimetic therapy is effective in lowering serum concentrations of fibroblast growth factor 23 (FGF23), which is a risk factor for left ventricular hypertrophy (LVH) and cardiovascular events in people with CKD (6, 7).